Navigation Links
Transplant Drug Shrinks Tumors in Women With Rare Lung Disease
Date:1/10/2008

Sirolimus reduced growths by 50% for sufferers of LAM

THURSDAY, Jan. 10 (HealthDay News) -- Women who are struck by a rare lung disease could find their tumors shrink by 50 percent with the help of the transplant drug sirolimus, a new study suggests.

The Cincinnati researchers who made the discovery also demonstrated the drug might improve lung function in some patients over time.

Lymphangioleiomyomatosis (LAM), a disease that exclusively targets women, is characterized by progressive loss of lung function due to the invasion of abnormal muscle tissue that obstructs airways. In its early stages, LAM can be confused with emphysema because of its effects on breathing. People with LAM often need oxygen treatments and lung transplants as the disease continues its course. According to the American Lung Association, as many as 250,000 women worldwide might have the disease.

The new treatment was also effective in reducing tumors in patients suffering from tuberous sclerosis complex (TSC), a rare genetic multi-system disease.

The two diseases share a genetic mutation that affects the activation of the enzyme mTOR, which is responsible for controlling the growth and spread of cells. Sirolimus, a drug that is usually prescribed to prevent the rejection of transplanted organs, also prevents mTOR activity, according to the researchers. Sirolimus is also known as rapamycin (Rapamune).

Publishing in the Jan. 10 edition of the New England Journal of Medicine, the researchers concluded that sirolimus has the potential to help patients with either disease avoid surgery for the tumor angiomyolipomata, common to both conditions.

"Less invasive therapies are clearly needed to treat the angiomyolipomata that people with TSC and LAM develop, and a drug that maintains or shrinks tumor size may reduce the need for procedures such as surgery," study author Dr. John Bissler, a physician/scientist in the division of nephrology and hypertension at Cincinnati Children's Hospital, said in a prepared statement. "Our data suggest that mTOR inhibition with sirolimus may hold promise for treating these and other disease manifestations in patients with TSC and LAM."

Bissler and his colleagues treated 20 patients who had angiomyolipomata tumors with sirolimus for 12 months. They reported that, at the end of the year, the tumors shrank by about half. Eleven of the patients who had LAM and took sirolimus for the year also showed a 10 percent to 15 percent improvement in expiratory air flow, a standard measure of lung function.

The researchers followed up with 18 of the original patients after a year without the sirolimus treatment. They found that tumor size had increased to about 85 percent of original pre-treatment size.

Tumors in five of the original patients, though, were 30 percent smaller than their original size after a year without the medication. The study authors theorized that this could be a result of apoptosis, a kind of programmed cell death.

After a year without treatment, the patients' lung function declined but was still better than what could be expected from similar patients after two years without any intervention, the researchers said. The improved lung function could be because of the lessening of obstructions and trapped gas in the lungs, the researchers noted.

Patients reported side effects from the sirolimus treatment that included mouth sores, diarrhea, upper respiratory infections and joint pain.

The researchers acknowledged that the small study needs further follow-up. A phase III clinical trial of the drug as a treatment for LAM patients is planned, they said.

More information

To learn more about LAM, visit the American Lung Association.



-- Madeline Vann



SOURCE: University of Cincinnati, news release, Jan. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rural Residents Get Fewer Organ Transplants: Study
2. Childrens Hospital physicians publish review of transplant issues in patients with biliary atresia
3. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
4. UCLA Program Aims to Revolutionize Kidney Transplants
5. Phylonix granted broad European patent for transplanting human cells into zebrafish
6. Transplanted Bone Marrow Cells Aid Nerve Regeneration
7. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
8. Partial Face Transplant Patient Doing Well
9. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
10. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
11. Cell Transplants Hold Promise for Heart Attack Survivors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transplant Drug Shrinks Tumors in Women With Rare Lung Disease
(Date:4/28/2017)... ... , ... It's not always common knowledge whether or not a certain sickness ... to whether or not they are contagious, and most people don't know the answer ... took a look into the matter. , They discovered that the main reason ...
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business ... and officers for 2017-2018. The annual board election process has been in place since ... basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
(Date:4/28/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published ... He does not. Yisrayl says with so many titles and names for the Creator, ... says with a little Scripture, backed with a lot of research, the truth is undeniable. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
Breaking Medicine Technology: